NervGen Pharma (TSE:NGEN) has released an update.
NervGen Pharma’s Chief Medical Officer will present a clinical trial update for NVG-291, a therapeutic peptide designed to repair nervous system damage, at the International Spinal Cord Society Annual Meeting. The presentation will discuss the trial’s design and early results, which aim to demonstrate NVG-291’s potential in promoting neural repair in spinal cord injuries (SCI).
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
